WO2018103433A1 - 癌转移透皮给药治疗器 - Google Patents

癌转移透皮给药治疗器 Download PDF

Info

Publication number
WO2018103433A1
WO2018103433A1 PCT/CN2017/103831 CN2017103831W WO2018103433A1 WO 2018103433 A1 WO2018103433 A1 WO 2018103433A1 CN 2017103831 W CN2017103831 W CN 2017103831W WO 2018103433 A1 WO2018103433 A1 WO 2018103433A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
therapeutic device
speed
transdermal
Prior art date
Application number
PCT/CN2017/103831
Other languages
English (en)
French (fr)
Inventor
李复生
李安
杨晓梅
Original Assignee
李复生
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201611119507.4A external-priority patent/CN106492343A/zh
Application filed by 李复生 filed Critical 李复生
Publication of WO2018103433A1 publication Critical patent/WO2018103433A1/zh

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H7/00Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Definitions

  • the invention belongs to a medical device, and more specifically relates to a medical device which combines massage and transdermal chemotherapy to treat cancer metastasis.
  • the fluorouracil from the intravenous infusion of fluorouracil is 5000mg, with the organs After systemic distribution, the fluorouracil that can be used to reach the cancer site is only 20mg, that is, only 0.4% of the drug reaches the cancerous foci, and the remaining 99.6% of the chemotherapeutic drugs act on normal cells and cause adverse reactions, which cause many patients to withstand The pain of chemotherapy adverse reactions.
  • the solution is to change the systemic intravenous chemotherapy route of administration, using other routes of chemotherapy.
  • Prior art tumor external application chemotherapy drugs mainly used for skin or body surface tumors, but due to the skin's ability to absorb drugs, it is necessary to add a transdermal agent to increase drug absorption. Even so, the efficacy is still limited. Transdermal administration is limited by physical properties. It is difficult to achieve quick-acting and cannot be treated with a large amount of drugs. It can only be used as an auxiliary treatment.
  • the object of the present invention is to provide a systemic intravenous chemotherapy for the prior art, which has the advantages of low therapeutic side effect and large inability to cure solid cancer, and provides a local administration and systemic administration according to the principle of tribochemistry.
  • the friction transdermal drug delivery device drives the friction head to rotate at a high speed and rubs against the rough friction cloth by the motor to generate high-strength squeezing force and friction heat generation effect, and promotes transdermal absorption chemotherapy of the chemotherapeutic drug.
  • the temperature of the skin coated with the external chemotherapy drug is 42-70 ° C, the stratum corneum produces a phase change and the soft gap increases.
  • the high-strength pressing force can quickly push the drug through the stratum corneum into the subcutaneous tissue through the rubbing cloth. Add blood circulation.
  • the definition of frictional collision in modern science is “the force that concentrates in a very short period of time” (see “Rubber”, 24 pages, Science Press).
  • the transdermal administration time of the present invention for the local transdermal and metastatic cancer lesions is 10-20 seconds, and the transdermal administration is performed along the lymphatic metastasis pathway and the hematogenous metastasis pathway. The time is 2 minutes, with short treatment time, small side effects, and can produce quick results.
  • Massage is a combination of pressure and friction, and its strength can be characterized by positive pressure and friction frequency. When the pressure area is small, the pressure intensity is large.
  • the rotation speed of the friction head can directly affect the magnitude of the friction force.
  • the amount of turbulent friction converted into the internal energy of the affected area is mainly determined by the rotational frequency.
  • the invention improves the shape of the friction head and the length of the extrusion chisel edge by increasing the rotation speed and the miniaturization of the friction head, and improves the extrusion strength and the heat generation temperature.
  • the amount of the drug can be increased through the stratum corneum to reach the deep tissue, in the systemic chemotherapy.
  • the transdermal drug delivery area is increased, a large amount of drug treatment can be used. The higher the motor speed, the higher the extrusion strength, the higher the heat generation temperature and the faster the heat production rate, and the more transdermal absorption of the drug.
  • the invention combines the mechanical energy and the thermal energy recovery function of the pressing friction input into the human body, and promotes the synergistic action together with the treatment of the cancer cells through the skin, and replaces the systemic intravenous chemotherapy by changing the administration route.
  • the therapeutic effect reduces the side effects of treating solid cancer to overcome the deficiencies of the prior art, thereby achieving the purpose of controlling elimination and cure of cancer metastasis.
  • a cancer metastasis transdermal therapeutic device which is a casing, a motor, a small friction head, a safety pad, a rough rubbing cloth, a fixing sleeve, and a positive Reverse speed switch, fluorouracil external preparation, in the area of the original cancer lesions and surrounding, metastatic lesions and surrounding, lymphatic metastasis and blood transfer sites, hand-held high-speed rotating therapeutic device for transdermal drug delivery to kill cancer cells
  • the holistic treatment supplemented by the recovery function, after the end of the treatment, the therapeutic device with a low-speed rotation is mainly used for restoring the function and transdermal administration to kill the cancer cells; the feature is that the motor is fixedly mounted inside the casing.
  • 16 small friction heads are arranged in a square shape and arranged in the casing.
  • the arrangement direction is parallel to the direction of the handle of the casing.
  • the bolts are bolted to the plane screw holes in the casing, and the motor drives the small
  • the friction head rotates at a high speed of 10,000 revolutions per minute.
  • the center of the small friction head is fixed to a cylinder with a radius from the center of the circle to the radius of the boundary of the circle.
  • the length of the chisel edge is a small friction head radius, which is in contact with the rough rubbing cloth for scraping and pressing friction; in the main stage of transdermal administration to kill cancer cells, first in the cancer lesion and surrounding, metastasis and surrounding, Lymphatic metastasis site and blood transfer site, coated with fluorouracil external preparation, hand-held high-speed rotary squeeze sliding friction treatment device for transdermal administration to kill cancer cells, recovery function supplemented by the overall treatment, and then adjust the direction of rotation and speed
  • the hand-held device with low-speed rotation and static friction is used to promote the drug absorption and recovery function in the above-mentioned parts, and the whole treatment is supplemented by transdermal administration.
  • the flat blade of the cylindrical head in the small friction head is a sharp angle.
  • the sliding friction is generated, the skin stratum corneum is squeezed and the heat is generated on the surface of the skin, and the drug is transmitted through the stratum corneum into the subcutaneous tissue.
  • the forward and reverse speed switch mounted on the handle portion of the casing is rotated backwards at a low speed, the chisel edge is raised at an obtuse angle, and the skin can be suctioned to generate static friction, and the subcutaneous tissue and the deep portion are pressed and generated. Heats up, promotes absorption of drugs in deep areas, and relaxes muscles to promote blood circulation recovery.
  • the high-speed rotation is mainly based on the flat action force, and the pressure is 0.1 kg/cm 2 . It is 2000 rev / min, 5000 rev / min, 10000 rev / min 3 grades; low speed rotation is mainly vertical pressure, the pressure is 0.5-1 kg / cm 2 , the speed is 300 rev / min, 600 rev / min 2 Grades.
  • the organic woven thread is sewn on the rough rubbing cloth, the surface is not smooth, and the frictional force can be increased.
  • the rough rubbing cloth is covered on the small friction head, and the fixing sleeve fixes the rough rubbing cloth on the casing.
  • the concentration of fluorouracil in the prior art is 1-10%, including 1-10% concentration of toxic drugs and valuable drugs, and the contact time with skin is several minutes and hours, while the single site contact liquid in the present invention does not exceed For 1 minute, consider increasing the concentration to about 1-30%.
  • the small friction head has a circular protrusion fixed at the lower part of the diameter of the circle, and the safety pad has 16 circular holes. The diameter of the circular hole is larger than the diameter of the small friction head, smaller than the circular annular protrusion of the small diameter of the small friction head, and the safety pad is small. After the friction head is bolted to the plane protruding screw hole in the casing to prevent the small friction head from coming out during high-speed rotation.
  • the diameter of the small friction head is 0.7 cm, and the friction head described in the prior art "Cancer Disease Therapeutic Apparatus" (ZL2006100699878) has a diameter of 1.5 cm, a diameter difference of more than 2 times, and a pressure area of 0.49 cm 2 . 2.25 square centimeters, a difference of 4 times.
  • the invention increases the extrusion strength by reducing the pressure area, and installs 16 small friction heads in the casing in which the four friction heads are originally installed, thereby increasing the pressure application point and increasing the rotation speed by 4 times to increase the efficiency.
  • the prior art squeezes the "one" shape, the "human” shape and the “+” shape arrangement to reduce the friction and smooth movement, which is not conducive to transdermal administration.
  • the use of a radius-length chisel edge does not reduce friction during high-speed rotation, thereby facilitating drug penetration through the stratum corneum.
  • other treatments and other configurations can also be used to achieve the objectives of the present invention.
  • the current status of treatment of cancer metastasis patients is mainly systemic intravenous chemotherapy, solid tumors, abdominal tumors (such as stomach, intestine, liver, gallbladder, pancreas and other solid malignant tumors) are also treated with systemic intravenous chemotherapy, postoperative adjuvant chemotherapy and Systemic intravenous chemotherapy was also used for adjuvant chemotherapy during surgery.
  • the effect is as follows: Must you use anticancer drugs? (Tianjin Science and Technology Press) Author [Day] Kondo said: "Generally for blood cancer, uterine villus cancer, testicular cancer, anticancer drugs not only have a prolonged effect, but also a healing effect.
  • anti-cancer drugs are not only ineffective, but will have side effects. Because anticancer drugs can not treat solid cancer, experts generally do not use "cancer cure” as an indicator. The real purpose of cancer metastasis treatment is to delay, but existing No matter how many clinical trials are repeated, the anti-cancer drug prolongation effect can not be confirmed. For example, the combination of chemotherapy and targeted therapy (Avastin) has not been proven, and anticancer drugs can significantly reduce the tumor. It is still impossible to prove that anticancer drugs have the effect of prolonging life, and the temporarily shrinking tumors will increase again. Anticancer doctors can only choose to show the shrinking of tumors instead of indicating the effect of life extension. The phenomenon of tumor shrinkage is very rare. Low-successful cases are certified and pose a significant risk to future patients.” Therefore, existing chemotherapy technologies exist. Body cancer can not be cured, not subsistence and appear repeatedly and generate insufficient side effects.
  • Cancer metastasis treatment is a holistic treatment combining structural anti-injury and recovery function.
  • the existing chemotherapy technology is effective in killing cancer cells, but lacks recovery function treatment, resulting in patients eventually still dying from systemic functional diseases.
  • Human life movement is a high-level form of exercise that combines mechanics, physics, and chemistry.
  • the reason why cancer metastasis can cause death is that it is a high-grade sports form of disease that requires advanced exercise techniques.
  • the existing chemotherapy technology is a primary exercise form treatment technology, which can not directly affect the advanced sports form of the disease, can only be an auxiliary treatment mode, can not cure solid cancer and has repeated and side effects.
  • massage therapy itself is a kind of health treatment method for restoring human body function, and has the purpose, selectivity and controllability, when it is combined with the chemotherapy drug for killing cancer cells, It is a holistic treatment method in which the structural anti-injury and recovery functions are mutually promoted, and the patient does not have a death factor of systemic functional disease, which can prolong the life of the patient. Because the metabolic function of the human body is the basis of life, it cannot be delayed without treating the decline in function. And the functional lesions around the cancer lesions are not treated, and the temporarily shrinking tumors will be repeated again due to the increase. Why can't chemotherapy treat solid cancer?
  • cancerous tissues and cancerous organs in solid cancer have large structural mechanical forces, chemical energy and thermal energy are molecular functions, lacking mechanical force, and can exert effects on cancer cells with less mechanical force, and cannot directly affect solid cancer.
  • the high-speed sliding sliding friction mechanical force and the generated surface high heat in the therapeutic device can pass the drug through the stratum corneum of the skin with strong mechanical force, the static friction mechanical force and the endogenous heat generated by the low-speed rotation in the therapeutic device.
  • the force can reach deep visceral tissues and bone surfaces, restore function and promote drug absorption.
  • the invention combines mechanical extrusion into a high-grade treatment technology combining sputum, physical heat-generating heat and chemical medicine, and can be used for prostate cancer, leukemia, lymphoma, breast cancer and lung, liver, stomach, esophagus, intestine, gallbladder, Cancer metastasis such as pancreas and solid cancer are treated curatively, rather than adjuvant therapy and palliative care.
  • the present invention details the principles and techniques related to transdermal chemotherapy for cancer metastasis.
  • the outermost layer of the human skin epidermis is a tough stratum corneum that overlaps approximately 20 layers and is a good barrier to physical and chemical stimuli from the outside world.
  • Drug-loaded liposomes allow many drugs to be administered through the skin, but in most cases, the drug remains in the upper part of the epidermis or in the upper part of the stratum corneum, which is effective in treating skin diseases, but is not suitable for systemic administration.
  • Transdermal delivery systems differ from topical topical skin preparations, which are targeted throughout the body and tissues.
  • NP, LS or emulsion can also be used as a drug carrier to promote drug absorption.
  • Fluorouracil is one of the main drugs currently used for the treatment of digestive tract tumors, but it is poorly absorbed, highly toxic, and is a polar and low fat-soluble drug. Although the molecular weight is low, it is still difficult to penetrate the stratum corneum of the skin. However, fluorouracil emulsion is particularly useful for inhibiting the metastasis of cancer cells through lymphatic vessels or for locally treating lymphoid tumors. In summary, it can be seen that the strength of the pressing force is a key factor for the transdermal absorption of the drug. When the present invention combines high-intensity squeezing force, high heat and skin absorption enhancer for transdermal administration, significant The role.
  • Transdermal drug delivery system can produce long-lasting, constant and controllable blood drug concentration, reduce toxic and side effects, avoid first-pass effect of liver and stomach, improve bioavailability; reduce the pain of injecting drug; convenient use of drugs and drug withdrawal; The number of doses and doses.
  • vasoconstrictor to the preparation, such as adding vasoconstrictor oxazoline (NPZ) to doxorubicin (ADR) ointment to make doxorubicin local
  • NPZ vasoconstrictor oxazoline
  • ADR doxorubicin
  • Drug massage known as the cream, as early as 2000 years ago, the Chinese Han Dynasty has widely used the cream and rubbing technology to treat diseases, is the main method of traditional Chinese medicine external treatment, is the massage therapy and drug external application of transdermal absorption of two different treatments Combined into one, the effect is better than the massage and drug external application alone.
  • the massage recovery function is treated at the same time as the transdermal chemotherapy, and the symmetrical combination can produce a high-level overall effect.
  • the prior art product series "Paster" ZL201620253944444 The schematic diagram of the technical index of the cream is shown in Figure 6 of the specification of the present invention.
  • the physical osmosis instrument in the prior art such as iontophoresis, electroporation, ultrasonic transdermal administration, etc., is only a physical osmotic instrument, which has no therapeutic significance and does not produce a holistic and significant effect.
  • 35 pages, 36 pages of fluorouracil mainly used for the treatment of digestive tract tumors, also commonly used in the treatment of breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer and skin cancer, or a larger dose of treatment of chorionic epithelial cancer. Fluorouracil 5%-10% ointment for external use, 2 times a day.
  • Alkylating agent hydrochloric acid mustard, mustard gas, thiotepa, carmustine, adenoma, and glycophosphorus.
  • Antimetabolites fluorouracil, hydroxyurea, cyclocytidine, cytarabine, and the like.
  • Antitumor antibiotic bleomycin.
  • Anti-tumor plants and Chinese herbal medicines camptothecin, cantharidin, zedoary turmeric oil, agrochemical base, colchicine, etc.
  • sitosterol sitosterol, polymyosin, interferon, transfer factor
  • This plaster can shrink a variety of tumors and prolong the life of cancer patients.
  • Drug release in the lesion may be more therapeutic than systemic blood concentration, focusing on killing cancer cells with less or no Injury to healthy cells has a very positive effect on improving the efficacy of chemotherapy drugs and prolonging and improving the lives of cancer patients.
  • the search for new transdermal penetration enhancers, transdermal techniques, and novel transdermal delivery vehicles for transdermal delivery systems is an important topic of research. China has developed a number of slow-release preparations and transdermal preparations, the vast majority of which are imitations. Innovations are needed in new technologies, new methods, and new approaches for targeted delivery, controlled release, and TTS (transdermal drug delivery systems).
  • Anti-cancer metastasis is the core problem of cancer treatment.
  • the high mortality rate of cancer metastasis patients indicates that the prevention and treatment principles and technical measures adopted for cancer metastasis should be summarized to change the current situation.
  • the main treatment method for common solid tumors is surgical resection. The operation has better effect on tumors with no early spread.
  • Surgery and radiotherapy are not effective for the treatment of metastatic tumors.
  • the current indicators for determining the efficacy of chemotherapy anticancer drugs include the following four points: 1 cancer cure. 2 extended life. 3 symptoms eased. 4 tumor shrinkage. Because anticancer drugs cannot treat solid cancer, experts generally do not use "cancer cure" as an indicator.
  • Curing cancer is a problem of the size of therapeutic technology.
  • Anticancer drugs alone cannot treat solid cancer, because chemical anticancer drugs are a form of primary exercise that cannot directly affect the high-grade motion of solid cancer.
  • Cancer drugs are restricted by symmetrical mechanical and physical lesions, and the effect of low efficacy and side effects is large.
  • the prior art (“non-surgical treatment of common tumors", Bu Ziying, 25 pages, Science Press) believes that artificial massage of the tumor and surrounding tissues, so that the tumor body is excessively squeezed can promote tumor metastasis.
  • the effect of massage alone is not the same as the effect it produces on the whole.
  • structural decision function and “function decision structure” alternately lead and play different roles in different stages of the development of the disease.
  • the “structure-determining function” is to determine some functions of the same level, rather than a high-level overall function; “functional decision structure” is a partial structure that determines the low-level structure of the overall function.
  • the prior art focuses on the study of structural parts and lacks an overall link between structural and functional parts. In the laws of nature, changes in quantity—quality change—new quantity changes, so that they transform each other and alternate with each other, constitute the eternal development process of things. Therefore, as long as the killing of cancer cells and the recovery of the disease function mutually promote the overall effect, following the correct treatment direction, the patient will not die.
  • the invention itself is also a massager, which adopts the traditional Chinese medicine recovery function to correct the liquid medicine for drug massage, and can have a significant effect on restoring the local and systemic functions of the human body.
  • the invention can be referred to the invention.
  • "ZL201410524366 ⁇ 9 specializes in the discussion of materials, and Figure 7 of the specification is also introduced.
  • tumor shrinkage is a problem in the development of lesions, can not represent the development trend of the lesion, only when the tumor shrinkage and functional recovery are integrated into one, it has substantial significance.
  • functional lesions are the basis of cancer cells, only killing cancer cells does not restore functional treatment, and tumors will appear repeatedly and again, and should be treated with both symptoms and root causes.
  • the deep recovery function of the sputum static friction in the therapeutic device can be combined with intratumoral injection, interventional chemotherapy, and intracavitary chemotherapy to kill cancer cells in local chemotherapy.
  • various cancers have "personality", “commonity” is the main one, and the present invention mainly studies the "commonness" of cancer.
  • the scientific hypothesis belongs to creative exploration. Under normal circumstances, the level of scientific hypothesis has a certain correspondence with the level of scientific research results.
  • FIG. 1 is a front view of a cancer metastasis transdermal therapeutic device of the present invention.
  • Figure 2 is a perspective view of the therapeutic device A of Figure 1.
  • Figure 3 (a) is a view of the therapeutic device B shown in Figure 1.
  • Figure 3 (b) is a projection view of Figure 3 (a) C-C.
  • Figure 4 is a view of the therapeutic device safety pad of Figure 1.
  • Figure 5 is a schematic diagram of the advanced exercise form treatment technique.
  • Figure 6 is a schematic diagram of the technical indicators of the cream.
  • Figure 7 is a schematic diagram of the process of cancer metastasis production and development.
  • Fig. 1 is a casing
  • 2 is a motor
  • 3 is a small friction head
  • 4 is a safety pad
  • 5 is a rough rubbing cloth
  • 6 is a fixing sleeve
  • 7 is Forward and reverse speed switch.
  • Figure 2 is a perspective view of the therapeutic device A of Figure 1.
  • Fig. 3(a) is a view of the therapeutic device B shown in Fig. 1
  • Fig. 3(b) is a projection view of Fig. 3(a) C-C.
  • Figure 4 is a view of the therapeutic device safety pad of Figure 1.
  • Figure 5 is a schematic diagram of the advanced exercise form treatment technique.
  • Figure 6 is a schematic diagram of the technical indicators of the cream.
  • Figure 7 is a schematic diagram of the process of cancer metastasis production and development.
  • a cancer metastasis transdermal therapeutic device consisting of a casing, a motor, a small friction head, a safety pad, a rough rubbing cloth, a fixed sleeve, a forward and reverse speed switch, and a fluorouracil external preparation, in the original cancer lesion and Surrounding, metastatic lesions and surrounding, lymphatic metastasis and blood transfer sites, with a high-speed rotating therapeutic device for transdermal administration to kill cancer cells, supplemented by a complementary overall treatment, holding a low-speed rotation after treatment
  • the therapeutic device performs the overall treatment with the recovery function as the main function and transdermal administration to kill the cancer cells;
  • the utility model is characterized in that: the motor is fixedly mounted in the casing, and 16 small friction heads are arranged in a square shape and arranged in the casing, and the arrangement direction Parallel to the direction of the handle of the casing, the safety pad is inserted into the small friction head and bolted to the convex hole of the inner casing of the casing
  • the motor drives the small friction head to rotate at a high speed of 10,000 rpm, and the small friction head is rounded to the center.
  • the length of the boundary radius is fixed to a cylinder, the plane of the head of the cylinder has a transverse blade protrusion, and the length of the lateral blade protrusion is a small friction head radius, which is scraped in contact with the rough friction cloth.
  • transdermal administration in the main stage of transdermal administration to kill cancer cells, first apply fluorouracil topical agents in the cancer lesions and surrounding, metastatic lesions and surrounding, lymphatic metastasis sites and blood transfer sites, hand-held high-speed rotary extrusion
  • the pressure-sliding friction therapeutic device performs transdermal administration to kill the cancer cells, and the recovery function is supplemented by the overall treatment, and then adjusts the rotation direction and the rotational speed, and the therapeutic device with the low-speed rotation and the static friction is used to promote the absorption of the drug at the above-mentioned site.
  • the object of the present invention is to treat the systemic intravenous chemotherapy in the prior art, and has the advantages of low curative effect and large inability to cure solid cancer in the treatment of cancer metastasis, and the combination of the recovery function treatment and the transdermal drug treatment promotes the overall treatment for the overall treatment.
  • the instrument of the invention treats cancer patients after operation and radiotherapy and chemotherapy in Qingdao Cancer Hospital, and treats adjacent sites and acupoints in tumor lesions, once every 10 minutes, once a day, 15 times for one course of treatment.
  • Many cancer patients suffer from side effects, physique, nausea, vomiting, hair loss, pain and loss of appetite due to chemoradiotherapy.
  • patients suffering from this invention have reduced pain, improved quality of life, and are easily chemoradiotherapy.
  • the treatment is simple and has no side effects, has been welcomed by doctors, patients are generally willing to accept, and hope to be self-operating implementation and improvement.
  • Pulmonary nodule solid lesion is a kind of lesion that may produce lung cancer.
  • the prior art diagnosis is mainly to check the chest scan CT every three months or so to observe whether it grows up in a short period of time. If it grows up, it needs surgery. Because of the difficulty in timely diagnosis and early surgical treatment of small pulmonary nodules, most of the lung cancer patients are in advanced stage at the time of diagnosis, and the treatment is relatively lagging when diagnosed.
  • drug treatment has no significant effect on pulmonary nodule disease, mainly through surgery, and there is a deficiency in low efficacy and side effects, and solid lesions are also the cause of difficulty in curing many advanced cancer patients.
  • the function-determining structure is the principle that the whole (organ) function determines the partial structure of the low-level (tissue), and the therapeutic device that uses the hand-held low-speed rotation and the sputum static therapy is used to perform the mechanical massage recovery function in the above-mentioned chest respiratory part.
  • the overall treatment of solid lesions is supplemented by administration.
  • Applicant Li Fusheng applied active blood for promoting blood circulation and removing blood stasis on the chest. Massage was performed with a massager. Once every night for 5 minutes, about 20 times were performed. The CT scan of the chest showed that the small pulmonary nodules disappeared.
  • Most of the small pulmonary nodules are benign lesions, such as inflammation, calcification, intrapulmonary lymph nodes, etc., and only a small part of malignant tumors such as early cancer or metastatic lung cancer.
  • Most benign lesions of small pulmonary nodules can produce significant curative effect by treating 10-20 times with the present invention, and a small part of malignant lesions of small pulmonary nodules, the treatment of the present invention does not produce significant curative effect, and treatment 3-5 times can produce obvious The discomfort of side effects should be confirmed by chest CT.
  • the anticancer drug can be used for local chemotherapy, and the whole treatment is mainly to kill cancer cells and supplement the function.
  • the diagnostic and therapeutic process of the present invention is 1-2 months, and the prior art diagnostic treatment process lasts for about one year. The invention can achieve the purpose of early diagnosis and early treatment of cancer.

Abstract

一种根据中医膏摩原理研制的癌转移透皮给药治疗器,由机壳(1)、电机(2)、小型摩擦头(3)、安全垫(4)、粗糙摩擦布(5)、正反向调速开关(7)、氟尿嘧啶外用药剂组成。该治疗器通过提高挤压强度和生热速度,促进化疗药物透皮吸收在组织深部和全身产生疗效,对实体癌和癌转移进行局部化疗和全身化疗,并降低副作用。在杀灭癌细胞为主阶段,先在原癌病灶部与周围、转移病灶部与周围、淋巴转移部位和血行转移部位,涂上氟尿嘧啶外用药剂,手持高速转动挤压滑动摩擦的治疗器进行透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,然后调整转动方向和转速,手持低速转动按揉静摩擦的治疗器,在上述部位进行恢复深层组织肌肉功能促进药物吸收为主、透皮给药为辅的整体治疗。

Description

癌转移透皮给药治疗器 技术领域
本发明属于医疗器械,更详细的讲是属于按摩与透皮给药化疗结合为一体治疗癌转移的医疗器械。
技术背景
现代医学把治愈癌症的希望放在早发现、早治疗上,但在癌转移后却无法治愈,癌症晚期患者90%死于癌转移。20世纪90年代以来,鉴于癌症手术后复发率、转移率仍很高,为了防止术后复发、转移,开始采用了术后系列辅助化疗,辅助化疗手段主要是全身静脉化疗,但其结果并不尽如人意,化疗对实体癌治疗效果有限,许多患者术后辅助化疗并未能阻止复发和转移。根据《癌症治疗新概念与新方法》58页、59页、65页,作者徐泽所述:在静脉滴注全身化疗时,从静脉滴注进入的化疗药氟尿嘧啶为5000mg,经随各脏器全身分布后,真正到达癌灶部位可以利用的氟尿嘧啶仅仅只有20mg,即只有0.4%的药物到达癌灶被利用,其余的99.6%的化疗药物均作用于正常细胞并产生不良反应,使许多患者承受着化疗不良反应的痛苦。鉴于全身静脉化疗给药途径的盲目性,导致用药量增大和不良反应,所以解决的办法是改变全身静脉注射化疗给药途径,采用其它化疗给药途径。
现有技术的肿瘤外敷化疗药:主要用于皮肤或体表肿瘤,但由于皮肤吸收药物的能力较小,需要加用透皮剂,以增加药物的吸收。但即使这样,疗效依然有限,透皮给药受物理性质限制存在着难以达到速效、不能用大量的药物治疗的不足,只能作为一种辅助治疗方式。
发明内容
本发明的目的在于,针对现有技术全身静脉注射化疗,在对癌转移治疗中存在着疗效低副作用大和不能治愈实体癌的不足,根据摩擦化学原理,提供一种可局部给药和全身给药的摩擦透皮给药装置,通过电机带动摩擦头高速转动与粗糙摩擦布相摩擦,产生高强度挤压力和摩擦生热效果,促进化疗药物进行透皮吸收化疗。当涂有外治化疗药物的皮肤受热温度在42-70℃时,角质层产生相变并变软间隙加大,高强度挤压力透过摩擦布可迅速推动药物穿过角质层进入皮下组织加入血液循环。现代科学对摩擦碰撞的定义是“在极短促的时间内集中作用的力”,(参见《摩擦》24页、科学出版社)。本发明对原癌病灶和转移癌病灶局部透皮给药时间是10-20秒,沿淋巴转移途径和血行转移途径往返移动进行透皮给药治疗 时间是2分钟,具有治疗时间短、副作用小,可以产生速效的特点。按摩是一种以按压力和摩擦共同作用的疗法,其作用强度可用正压力和摩擦频率来表征。压力面积小则压力强度大,摩擦头转动速度可以直接影响摩擦力的大小,揉动摩擦转化为患处内能的多少,主要由转动频率决定。本发明通过提高转速、摩擦头小型化改进摩擦头形状和挤压横刃长度,提高挤压强度和产热温度,在局部化疗时可加大药物透过角质层数量达到组织深部,在全身化疗时加大透皮给药面积可采用大量药物治疗。电机转速越高,挤压强度越高,产热温度越高与产热速度越快,透皮吸收药物越多。本发明将按压摩擦输入人体的机械能、热能恢复功能治疗,与透过皮肤输入化疗药物杀灭癌细胞治疗相互促进共同作用进行整体性对病因治疗,通过改变给药途径替代全身静脉注射化疗,提高疗效降低副作用治疗实体癌,以克服现有技术的不足,从而达到对癌转移进行控制消除和治愈的发明目的。
为了达到上述发明目的,本发明是通过以下技术方案进行的:一种癌转移透皮给药治疗器,它是由机壳、电机、小型摩擦头、安全垫、粗糙摩擦布、固定套、正反向调速开关、氟尿嘧啶外用药剂组成,在原癌病灶部和周围、转移病灶部和周围、淋巴转移部位和血行转移部位,手持高速转动的治疗器进行以透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,治疗结束后手持低速转动的治疗器进行以恢复功能为主、透皮给药杀灭癌细胞为辅的整体治疗;其特征在于:机壳内固定安装电机,16支小型摩擦头成正方形排列安装在机壳内,排列方向与机壳的手把方向平行,安全垫套入小型摩擦头后用螺栓与机壳内平面凸起螺孔联接固定,电机带动小型摩擦头每分钟10000转高速转动,小型摩擦头圆中心到圆边界半径长度固定一圆柱,圆柱头部平面有一横刃凸起,横刃凸起长度是小型摩擦头半径,与粗糙摩擦布接触进行刮削挤压摩擦;在透皮给药杀灭癌细胞为主阶段,先在癌病灶部与周围、转移病灶部与周围、淋巴转移部位和血行转移部位,涂上氟尿嘧啶外用药剂,手持高速转动挤压滑动摩擦的治疗器进行透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,然后调整转动方向和转速,手持低速转动按揉静摩擦的治疗器在上述部位进行促进药物吸收恢复功能为主、透皮给药为辅的整体治疗。
小型摩擦头中圆柱头部平面横刃凸起是尖锐角,当向前高速转动时产生滑动摩擦,挤压皮肤角质层并在皮肤表面摩擦生热,促进药物透过角质层进入皮下组织。当通过安装在机壳手把部的正反向调速开关向后低速转动时,横刃凸起成钝角,可吸定压紧皮肤产生静摩擦,对皮下组织和深层部位进行按揉和产生内生热,促进深层部位药物吸收,并放松肌肉促进血液循环恢复功能。其中高速转动时以平动作用力为主,压力是0.1公斤/平方厘米,转速 是2000转/分钟、5000转/分钟、10000转/分钟3个档次;低速转动时以垂直压力为主,压力是0.5-1公斤/平方厘米,转速是300转/分钟、600转/分钟2个档次。粗糙摩擦布上缝有机织线,表面不光滑,可以增大摩擦力,粗糙摩擦布盖在小型摩擦头上,固定套将粗糙摩擦布固定在机壳上。现有技术临床外用药物浓度氟尿嘧啶是1-10%,包括毒剧药及贵重药也是1-10%浓度,与皮肤接触时间为数拾分钟和数小时,而本发明中单一部位接触药液不超过1分钟,可以考虑加大浓度为1-30%左右。小型摩擦头圆直径下部固定有圆环状凸起,安全垫有16个圆孔,圆孔直径大于小型摩擦头圆直径,小于小型摩擦头圆直径下部圆环状凸起,安全垫套入小型摩擦头后用螺栓与机壳内平面凸起螺孔联接固定,以防止小型摩擦头在高速转动中脱出。小型摩擦头的圆直径为0.7厘米,而现有技术《癌症疾病治疗器》(ZL200610069987·8)实施例中记载的摩擦头直径为1.5厘米,直径相差2倍以上,压力面积是0.49平方厘米与2.25平方厘米,相差4倍。本发明通过减少压力面积加大挤压强度,并在原先安装4个摩擦头的机壳内安装16个小型摩擦头,增大了压力作用点,转速提高了4倍以增加效率。在摩擦头面积小型化时,现有技术中挤压横刃“一”字型、“人”字型和“+”字型排列会降低摩擦力,成平滑移动,不利于透皮给药,采用半径长度横刃在高速转动中不会降低摩擦力,从而促进药物透过角质层。在进行结构与功能相互依存整体治疗中,采用其它治疗方式和其它构型亦可达到本发明的目的。
现有技术的不足
当前,癌转移患者治疗的现状,主要为全身静脉注射化疗,实体瘤、腹腔肿瘤(如胃、肠、肝、胆、胰等实体恶性肿瘤)也均采用全身静脉化疗,术后辅助化疗和围术期辅助化疗也采用全身静脉化疗。其效果如《一定要用抗癌药吗?》(天津科学技术出版社)作者[日]近藤诚所说:“一般对于血液癌、子宫绒毛癌、睾丸癌,抗癌药不但具有延命效果,还有治愈效果。但是对于肺癌、肝癌、胃癌等其它实体癌,抗癌药不仅无效,反而会产生副作用。由于抗癌药无法治疗实体癌,所以专家们一般不将“癌症治愈”作为指标。癌转移治疗的真正目的是延命,但是现有技术不管重复进行多少次临床试验,都无法证实抗癌药延命效果,如联合化疗方法和靶向治疗药物(安维汀)延命效果并没有得到证明,抗癌药可以使肿癌出现明显的缩小;仍然无法证明抗癌药就有延长生命的效果,暂时缩小的肿瘤还会再次增大,抗癌医生们只能选择展示肿瘤缩小的情况来取代说明延命效果。肿瘤缩小的现象非常少见,极低的成功病例便通过认证,会对未来患者造成极大风险。”所以,现有化疗技术存在着对实体癌不能治愈,不能延命和出现反复并产生副作用的不足。
本发明的治疗原理和特点
1、人体是结构与功能相互依存的统一体,缺少其中之一,统一体将失去存在的意义,癌转移治疗是结构抗损伤与恢复功能相结合的整体治疗,缺一不可。现有化疗技术在杀灭癌细胞方面效果显著,但是缺乏恢复功能治疗,导致患者最终依然死于全身功能病变。人体生命运动是机械、物理、化学相结合的高级运动形式,癌转移之所以会致人死亡,在于它是一种高级运动形式病变,需要采用高级运动形式技术治疗。现有化疗技术是一种初级运动形式治疗技术,不能对高级运动形式病变产生直接作用,只能是一种辅助治疗方式,不能治愈实体癌并出现反复和产生副作用。
2、本发明的特点是:按摩疗法本身就是一种恢复人体功能的养生治疗方法,具有目的性、选择性和可控性,当它与杀灭癌细胞的化疗药物结合为一体共同作用时,是一种结构抗损伤与恢复功能相互促进的整体治疗方式,患者不会出现全身功能病变死亡因素,能够延长患者生命。因为人体代谢功能是生命存在的基础,不对功能下降进行治疗,便不能延命。并且癌病灶周围功能病变不治疗,暂时缩小的肿瘤还会因再次增大,出现反复。化疗为什么不能治疗实体癌?因为实体癌中癌组织和癌器官具有较大的结构机械力,化学能和热能是分子功能,缺乏机械作用力,可以对机械力较小的癌细胞产生作用,不能对实体癌产生直接作用。治疗器中高速转动的滑动挤压摩擦机械力和产生的表面高热,可以使药物透过结构机械力强的皮肤角质层,治疗器中低速转动的按揉静摩擦机械力和产生的内生热,作用力可达内脏深层组织和骨骼表面,恢复功能和促进药物吸收。本发明将机械挤压按揉、物理产热送热、化学药物结合为一体的高级治疗技术,可以对前列腺癌、白血病、淋巴癌、乳腺癌和肺、肝、胃、食道、肠、胆、胰等癌转移和实体癌进行治愈性治疗,而不是辅助治疗和姑息治疗。
为了充分公开发明创造,本发明对透皮给药化疗治疗癌转移相关原理与技术,进行详细说明。
一、透皮给药的研究现状
人体皮肤表皮的最外层是大约重叠20层的坚韧角质层,它是对来自外界物理和化学刺激的很好屏障。载有药物的脂质体可使许多药物透过皮肤给药,但大部分情况下,药物均滞留在表皮的上部或角质层上部,治疗皮肤病有效,但对于全身给药却不太合适。透皮给药系统不同于作用限于局部的外用皮肤制剂,透皮给药制剂的目标是在全身和组织深部。根据德国慕尼黑大学的研究,如用脂质体作载体时,在皮肤各层不同水合程度而产生的水渗透压力下,载体可变形而顺利穿过孔径是其自身大小五分之一甚至十分之一的皮肤通道而自身 完整体不受影响。其机理是当传递体在受到外界压力及空间制约时就会发生形变,极易穿过比其直径小几倍的通道。在药剂学促渗作用研究方面,还可用NP、LS或乳剂作为药物载体促进药物的吸收。
氟尿嘧啶是目前用于治疗消化道肿瘤的主要药物之一,但吸收差、毒性较大,并是一种极性的和低脂溶性药物,虽然分子量低,仍难以透过皮肤角质层。但氟尿嘧啶乳剂对抑制癌细胞经淋巴管的转移、或局部治疗淋巴系统肿瘤特别有用。综上所述可以看到,挤压力强度是药物透皮吸收的关键因素,当本发明将高强度挤压力、高热和皮肤吸收促进剂结合在一起进行透皮给药时,会产生显著的作用。透皮给药系统(TTS)可产生持久、恒定和可控的血药浓度,减轻毒副作用,避免肝胃首过效应,提高生物利用度;减轻注射用药的痛苦;用药及停药方便;减少给药次数和剂量。假如不希望药物经皮吸收产生全身治疗作用,可在制剂中加入血管收缩剂,如在阿霉素(ADR)软膏中加入血管收缩剂硝酸荼唑啉(NPZ),可使阿霉素在局部皮肤保持较高浓度。所以,充分利用现有药物通过剂型和透皮给药系统的研究,有可能找到更优秀的解决方案,从而提高癌转移的治愈率或者延长患者的生存期、提高生活质量。
二、按摩与透皮给药化疗相结合的原理
临床数据表明,癌症患者在术后即使进行规范化的治疗,但仍有大部分患者会复发,而目前手术放化疗治疗癌症时,并未对患者的内环境进行整体的治疗,所以癌症的转移复发是再所难免的,必须在针对局部病变部位治疗的同时,改变患者的内环境,才能真正治愈癌症。现代系统科学说明:事物整体的特征不能从部分的知识中推演出来,系统是要素及其关系的整合。结构治疗的效果只能通过与功能治疗相结合的整体性来加以说明,如果结合方式发生变化,这些效果就会构成其它事物。
药物按摩,古称膏摩,早在2000年前我国汉代就已经广泛开始采用膏摩技术治疗疾病,是传统中医药外治的主要方法,是将按摩疗法与药物外敷透皮吸收两种不同的治疗结合为一体,效果优于按摩和药物外敷单独治疗效果。根据膏摩原理研制的本发明,在透皮给药化疗的同时进行了按摩恢复功能治疗,对称结合可以产生高层次整体性效果,具体详细说明参见现有技术本系列产品《膏摩器》ZL2016202539444中《膏摩技术指标示意图》,在本发明说明书附图6。现有技术中的物理促渗仪器,如离子电渗析、电致孔、超声透皮给药等,只是一种物理促渗仪器,本身没有治疗意义,不会产生整体性显著效果。
三、透皮给药化疗中所用抗癌药物
关于应用外治药物的性质:清代著名外治宗师吴师机在《理瀹骈文》中认为“外治之药亦即内治之药”,《经皮给药新剂型》69页作者郑俊民认为“(透皮药物)应当考虑选用适当浓度的药液,尤其是剧毒药及贵重药物,目前临床常用浓度为1%-10%左右”。日本武田药品工业编著的“生命科学——药物输送系统”,(参见日本经济计划厅综合计划局编《推动经济的2010年的技术预测101项》),书中认为:“药物输送系统是新一代的治疗方法,为取得突破所必须的关键技术有对药物经过皮肤、粘膜吸收机理的研究,……使用过去因为副作用不能开发的化合物。”本发明采用外治药剂种类较广泛,现提供以下外治透皮药物供参考。
1、根据《新编肿瘤药物手册》付桂英主编金盾出版社2016年4月第1版。
35页、36页氟尿嘧啶:主要用于治疗消化道肿瘤,亦常用于治疗乳腺癌、卵巢癌、肺癌、宫颈癌、膀胱癌及皮肤癌等或较大剂量治疗绒毛膜上皮癌。氟尿嘧啶5%-10%软膏外用,每日2次。
421页阿魏化痞膏:功能主治,化痞消积。用于气滞血凝、症瘕痞块、脘腹疼痛、胸胁胀满。适用于肝、胆、胃、肺、食管、肠、膀胱、肾等诸脏腑及妇科肿瘤痞块。本方含生川乌、生草乌、雄黄、樟脑等有毒药物,皮肤破溃及皮肤过敏者不宜应用。外用加温软化,贴于脐上或患处。类别:药典品种、处方药。附:本器械应用可将药膏稀释。
2、《新编外用药物手册》于秀路等主编,山东科学技术出版社,1996年9月第1版218页—225页,可供外用的抗肿瘤药物分类:
烷化剂:盐酸氮芥、芥子气、噻替呱、卡氮芥、消瘤芥、甘磷酰芥等。
抗代谢药:氟尿嘧啶、羟基脲、环胞苷、阿糖胞苷等。
抗肿瘤抗生素:博莱霉素。
抗肿瘤植物及中草药:喜树碱、斑蝥素、莪术油、农吉利碱、秋水仙素等。
激素:戊酸雌二醇
杂类:谷固醇、聚肌胞、干扰素、转移因子
3、《膏敷疗法》张奇文主编、中国医药科技出版社、2013年4月第1版
358页、抗癌膏。本膏药能使多种肿瘤缩小,可延长癌症病人的生命。适应病症:肺癌、鼻咽癌、食管癌、胃癌、肠癌、肝癌、乳腺癌、膀胱癌、白血病。
4、《药剂学发展与展望》吴镭、平其能主编、化学工业出版社、2002年7月第1版。
94页、95页:我国的TTS(透皮给药系统)研究主要集中在脂质体、离子导入、 透皮促进剂筛选及透皮机理研究。研制了油酸、复方唐松草新碱、复方氟尿嘧啶、喜树碱、甲氨蝶呤、环磷酰胺、多糖类及顺铂等多相脂质体。目前我国已有两性霉素B、多柔比星、紫杉醇等药物脂质体获准进入临床研究。9页、13页、14页,经皮给药制剂的目标是在全身或组织深部,在病灶部位释放药物则可能比全身血药浓度更有治疗意义,集中杀灭癌细胞而较少或不损伤健康细胞,对提高化疗药物的效果和延长、改善肿瘤病人的生命,具有十分积极的意义。38页、131页、141页,对于透皮给药系统,寻找新的透皮促渗剂、透皮技术和新型透皮给药载体是研究的重要课题。我国已经开发了许多的缓控释制剂和透皮制剂,绝大多数是仿制品种。需要在定向输送、控释和TTS(透皮给药系统)的新技术、新方法、新途径等方面加强创新。
四、总结
疾病概念是对疾病本质认识的概括,从而决定疾病的防治原则和技术措施。抗癌转移是癌症治疗的核心问题,癌转移患者出现如此高的死亡率,表明应当对癌转移采取的防治原则和技术措施进行总结,改变现有状况。常见实体性肿瘤目前主要治疗方法是手术切除,手术对早期没有扩散的肿瘤效果较好,手术与放疗对已有转移肿瘤治疗效果不好。当绝大多数患者在医院进行了手术后,接受化疗,均为全身静脉化疗。目前判定化疗抗癌药效果的指标包括以下4点:①癌症治愈。②延命。③症状缓和。④肿瘤缩小。由于抗癌药无法治疗实体癌,所以专家们一般不将“癌症治愈”作为指标。
1、治愈癌症是一个治疗技术作用力大小的问题,单靠抗癌药无法治疗实体癌,因为化学性质抗癌药是一种初级运动形式,不能对实体癌高级运动形式病变产生直接作用,抗癌药受对称的机械物理病变制约,出现疗效低副作用大的效果。现有技术(《常见肿瘤的非手术治疗》卜子英著25页,科学出版社)认为:对肿瘤及其周围组织人工按摩,使肿瘤实体过度受到挤压可以促进肿瘤的转移。但是按摩单独作用效果与它在整体中产生的效果是不一样的,当按摩与化疗共同作用时,脱落转移的癌细胞会被杀死,机械物理功能下降得到恢复,整体治疗实体癌可以产生显著效果。人体生命运动是由物理、化学相互依存组成的高级运动形式,在生命运动中物理规律与化学规律服从生命高级运动形式的整体规律,高级运动形式治疗技术是以治愈为目标,与初级运动形式技术对症治疗不同。所以,整体的性质不能从部分的变化中得到改变,单靠抗癌药无法治疗实体癌,但高级运动形式的整体治疗,可以将“治愈癌症”作为指标。可参照说明书附图5。
2、延命是一个治疗方向是否符合自然规律的问题,如《肺癌转移》(人民卫生出 版社2011年6月284页)[美]密歇根大学Venkeshwarke Shamooni,作者所述:“手术放化疗和各种杀灭癌细胞治疗技术,可以对消除、控制癌症转移病灶产生明显的效果,但至今不清楚局部控制大多数微转移灶后为什么不能改善患者的生存,因为大多数接受局部治疗的癌转移患者最终死于疾病全身进展,而不是局部破坏”。上述疾病全身进展是全身功能病变,是死亡主要因素。现代医学认为是“结构决定功能”,只进行结构为主治疗,不进行功能为主治疗是导致患者死亡的主要原因。而“结构决定功能”与“功能决定结构”两种不同变化形式,在病变发展过程中的不同阶段交替领先主导,起到不同的作用。其中“结构决定功能”,是决定同层次的部分功能,而不是高层次的整体功能;“功能决定结构”是整体功能决定低层次的部分结构。现有技术注重对结构部分的研究,缺乏对结构部分与功能部分的整体联系研究。在自然规律中,从量变——质变——新的量变,如此相互转化、相互交替,构成了事物永恒的发展过程。所以,只要杀灭癌细胞与恢复病变功能相互促进整体作用,遵循正确的治疗方向,患者就不会死亡。本发明本身也是一种按摩器,采用中医恢复功能补正药液进行药物按摩,可以对恢复人体局部与全身功能产生显著效果,关于如何具体详细延长患者生命,可以参照本系列发明《肝癌转移治疗器》ZL201410524366·9中专门论述资料,说明书附图7也进行了介绍。
3、肿瘤缩小是病变发展过程中的一个问题,不能代表病变的发展趋势,只有当肿瘤缩小与功能恢复结合为一体时,才有实质意义。因为功能病变是癌细胞产生的基础,只杀灭癌细胞不恢复功能治疗,肿瘤还会出现反复再次增大,应当标本兼治。治疗器中的按揉静摩擦深层次恢复功能治疗,可以与局部化疗中的肿瘤内注药、介入化疗、腔内化疗杀灭癌细胞相结合。根据现有技术对癌转移复发的研究认为:尽管各种癌症各有“个性”,但“共性”却是主要的,本发明主要是对癌症的“共性”进行研究的。
“科学假说属于创造性的探索,一般情况下,科学假说的水平与科研成果的水平有一定的对应关系。
一般水平的科学假说+一般科研仪器、设备=低水平的科研成果。
一般水平的科学假说+高、精、尖的科研仪器、设备=中等水平的科研成果。
高水平的科学假说+一般科研仪器、设备=高水平的科研成果”。
参见《医学科技哲学导论》贺达仁著、高等教育出版社,2005年第104页。
综上所述,医学发展所取得一切成果,都只能是人类关于人体生命认识长河中的一个阶段,需要不断的创新发展。目前应用治疗器样机结合药物外治已经在治疗腹部常见疾 病方面取得了显著的效果,希望在治疗癌转移方面取得进展,尽快为患者解除痛苦。
附图说明
图1是本发明癌转移透皮给药治疗器主视图。
图2是图1所示治疗器A向视图。
图3(a)是图1所示治疗器B向视图。
图3(b)是图3(a)C-C的投影视图。
图4是图1所示治疗器安全垫视图。
图5是《高级运动形式治疗技术示意图》。
图6是《膏摩技术指标示意图》。
图7是《癌转移产生与发展过程示意图》
具体实施方式
本发明的图1所示癌转移透皮给药治疗器中:1是机壳,2是电机,3是小型摩擦头,4是安全垫,5是粗糙摩擦布,6是固定套,7是正反向调速开关。图2是图1所示治疗器A向视图。图3(a)是图1所示治疗器B向视图,图3(b)是图3(a)C-C的投影视图。图4是图1所示治疗器安全垫视图。图5是《高级运动形式治疗技术示意图》。图6是《膏摩技术指标示意图》。图7是《癌转移产生与发展过程示意图》。
一种癌转移透皮给药治疗器,它是由机壳、电机、小型摩擦头、安全垫、粗糙摩擦布、固定套、正反向调速开关、氟尿嘧啶外用药剂组成,在原癌病灶部和周围、转移病灶部和周围、淋巴转移部位和血行转移部位,手持高速转动的治疗器进行以透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,治疗结束后手持低速转动的治疗器进行以恢复功能为主、透皮给药杀灭癌细胞为辅的整体治疗;其特征在于:机壳内固定安装电机,16支小型摩擦头成正方形排列安装在机壳内,排列方向与机壳的手把方向平行,安全垫套入小型摩擦头后用螺栓与机壳内平面凸起螺孔联接固定,电机带动小型摩擦头每分钟10000转高速转动,小型摩擦头圆中心到圆边界半径长度固定一圆柱,圆柱头部平面有一横刃凸起,横刃凸起长度是小型摩擦头半径,与粗糙摩擦布接触进行刮削挤压摩擦;在透皮给药杀灭癌细胞为主阶段,先在癌病灶部与周围、转移病灶部与周围、淋巴转移部位和血行转移部位,涂上氟尿嘧啶外用药剂,手持高速转动挤压滑动摩擦的治疗器进行透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,然后调整转动方向和转速,手持低速转动按揉静摩擦的治疗器在上述部位进行促进药物吸收恢复功能为主、透皮给药为辅的整体治疗。
其具体的实施例为:
本发明的目的,针对现有技术全身静脉注射化疗,在对癌转移治疗中存在着疗效低副作用大和不能治愈实体癌的不足,采用恢复功能治疗治疗与透皮药物治疗相互促进共同作用进行整体治疗,达到提高疗效降低副作用治疗实体癌的发明目的。本发明仪器在青岛市肿瘤医院对手术和放化疗后癌症患者进行治疗,在肿瘤病灶相关临近部位和穴位治疗,每次10分钟,每日一次,15次为一疗程。许多癌症患者由于手术放化疗后副作用大,体质下降,恶心、呕吐、掉头发、痛疼和食欲不振,而接受本发明创造治疗后患者痛苦减轻、生存质量提高、容易接受放化疗、疗效较好,并且治疗方法简单和无副作用,受到了医生的欢迎,患者们普遍乐于接受,并希望能够自我操作实施和改进提高。
肺小结节实体病变是一种可能产生肺癌的病变,现有技术诊断主要是每三个月左右复查一次胸部平扫CT,以观察是否在短期内长大,如长大就需手术治疗,由于肺小结节很难及时诊断与早期手术治疗,大部分的肺癌患者在诊断时已属晚期,等确诊时治疗也相对滞后。现有技术中药物治疗对肺小结节病没有显著效果,主要是通过手术进行治疗,存在着疗效低副作用大的不足,实体病变也是许多癌症晚期患者难以治愈的原因。功能决定结构是整体(器官)功能决定低层次(组织)的部分结构的原理,采用手持低速转动按揉静疗擦的治疗器,在上述胸部呼吸器官部位进行机械按摩恢复功能为主、透皮给药为辅的对实体病变整体治疗。申请人李复生在胸部涂上活血化瘀的活络油,采用按摩器进行按摩,每天晚上一次,每次5分钟,一共大约进行了20次左右,胸部平扫CT显示,肺小结节消失,(青岛市第三人民医院医学影像科胸部平扫CT影像号:A0128516—001、A0145981-001、A0163183-001、A0180031-001),胸部呼吸器官病变症状显著减轻,实施本发明取得了意料不到的技术效果,克服了现有技术的不足。
肺小结节大部分是良性病变,如炎症、钙化、肺内淋巴结等,早期癌症或转移性肺癌等恶性肿瘤只占一小部分。肺小结节大部分良性病变,通过本发明治疗10-20次可产生显著疗效,而肺小结节小部分恶性病变,本发明治疗不会产生显著疗效,并且治疗3-5次可产生明显副作用的不适现象,应当采用胸部CT进行确诊。如确诊,可在本发明中采用抗癌药物进行局部化疗,进行以杀灭癌细胞为主、恢复功能为辅的整体治疗。本发明的诊断治疗过程为1-2个月,而现有技术的诊断治疗过程长达一年左右,实施本发明可以达到对癌症早诊断早治疗的目的。

Claims (1)

  1. 一种癌转移透皮给药治疗器,它是由机壳、电机、小型摩擦头、安全垫、粗糙摩擦布、固定套、正反向调速开关、氟尿嘧啶外用药剂组成,在原癌病灶部和周围、转移病灶部和周围、淋巴转移部位和血行转移部位,手持高速转动的治疗器进行以透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,治疗结束后手持低速转动的治疗器进行以恢复功能为主、透皮给药杀灭癌细胞为辅的整体治疗;其特征在于:机壳内固定安装电机,16支小型摩擦头成正方形排列安装在机壳内,排列方向与机壳的手把方向平行,安全垫套入小型摩擦头后用螺栓与机壳内平面凸起螺孔联接固定,电机带动小型摩擦头每分钟10000转高速转动,小型摩擦头圆中心到圆边界半径长度固定一圆柱,圆柱头部平面有一横刃凸起,横刃凸起长度是小型摩擦头半径,与粗糙摩擦布接触进行刮削挤压摩擦;在透皮给药杀灭癌细胞为主阶段,先在癌病灶部与周围、转移病灶部与周围、淋巴转移部位和血行转移部位,涂上氟尿嘧啶外用药剂,手持高速转动挤压滑动摩擦的治疗器进行透皮给药杀灭癌细胞为主、恢复功能为辅的整体治疗,然后调整转动方向和转速,手持低速转动按揉静摩擦的治疗器在上述部位进行促进药物吸收恢复功能为主、透皮给药为辅的整体治疗。
PCT/CN2017/103831 2016-12-08 2017-09-28 癌转移透皮给药治疗器 WO2018103433A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201611119507.4 2016-12-08
CN201621339403.X 2016-12-08
CN201611119507.4A CN106492343A (zh) 2016-12-08 2016-12-08 癌转移透皮给药治疗器
CN201621339403 2016-12-08

Publications (1)

Publication Number Publication Date
WO2018103433A1 true WO2018103433A1 (zh) 2018-06-14

Family

ID=62491759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/103831 WO2018103433A1 (zh) 2016-12-08 2017-09-28 癌转移透皮给药治疗器

Country Status (1)

Country Link
WO (1) WO2018103433A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144080A (zh) * 1995-08-29 1997-03-05 李复生 脏腑疾病治疗器
CN101120904A (zh) * 2006-11-13 2008-02-13 李复生 癌症疾病治疗器
WO2012011661A2 (ko) * 2010-07-21 2012-01-26 경북대학교 산학협력단 자동 침분비 촉진 장치
CN103126866A (zh) * 2012-08-30 2013-06-05 李复生 癌症扩散转移治疗器
CN204636935U (zh) * 2015-04-21 2015-09-16 李安 腰腿痛按摩器
CN105147510A (zh) * 2015-07-16 2015-12-16 杜静 颈椎按摩器
CN106492343A (zh) * 2016-12-08 2017-03-15 李复生 癌转移透皮给药治疗器

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1144080A (zh) * 1995-08-29 1997-03-05 李复生 脏腑疾病治疗器
CN101120904A (zh) * 2006-11-13 2008-02-13 李复生 癌症疾病治疗器
WO2012011661A2 (ko) * 2010-07-21 2012-01-26 경북대학교 산학협력단 자동 침분비 촉진 장치
CN103126866A (zh) * 2012-08-30 2013-06-05 李复生 癌症扩散转移治疗器
CN204636935U (zh) * 2015-04-21 2015-09-16 李安 腰腿痛按摩器
CN105147510A (zh) * 2015-07-16 2015-12-16 杜静 颈椎按摩器
CN106492343A (zh) * 2016-12-08 2017-03-15 李复生 癌转移透皮给药治疗器

Similar Documents

Publication Publication Date Title
WO2008058452A1 (fr) Équipement de traitement du cancer
CN102078391A (zh) 一种治疗颈肩腰腿疼痛的药物
CN106492340A (zh) 胃癌转移治疗器
WO2018103433A1 (zh) 癌转移透皮给药治疗器
CN203354845U (zh) 肺癌转移治疗器
CN103735620A (zh) 一种治疗痔疮的纳米乳原位凝胶
CN202822479U (zh) 尿毒症皮肤透析治疗器
CN104207926B (zh) 肝癌转移治疗器
WO2018082416A1 (zh) 胃癌转移治疗器
CN103263333A (zh) 肺癌转移治疗器
CN204092533U (zh) 肝癌转移治疗器
CN205698195U (zh) 膏摩器
CN105878393A (zh) 一种止痛贴剂及其制备方法
CN106492343A (zh) 癌转移透皮给药治疗器
CN104707041B (zh) 用于痔疮手术后的护理药物
CN104147261B (zh) 一种治疗风湿性关节炎的中药制剂
CN105641346A (zh) 一种无毒副作用的透皮镇痛药及其制备方法
US20160081874A1 (en) Therapeutic device for lung cancer metastasis
CN103800874B (zh) 一种熏蒸治疗脑中风偏瘫肢体功能障碍的药物组合物
CN1152704C (zh) 抗癌口服液及其制备方法
CN103816522A (zh) 治疗乳腺增生的中药
CN108310176A (zh) 一种针对晚期肝癌癌痛患者的纳米中药制剂透皮贴
CN1243565C (zh) 中药止痛袋
CN106074956A (zh) 一种用于ct增强扫描造影剂渗漏治疗的中药组合物
CN106074849A (zh) 一种动静脉穿刺用扩张血管止痛消炎贴

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17878829

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17878829

Country of ref document: EP

Kind code of ref document: A1